Highlights from

EAN 2020

European Academy of Neurology

Virtual 23 - 26 May 2020

Real-world data for erenumab in Germany

Based on the assessment of treating physicians, erenumab reduced the burden of migraine and increased the quality of life (QoL) in over 75% of their migraine patients. These were the main results of the TELESCOPE study, providing real-world data for erenumab in Germany [1].

By means of an online survey from July-December 2019, data from 45 headache centres across Germany were collected. The interim analysis included 542 patients. Half of these had episodic migraine, half had chronic migraine. A total of 45 physicians reported that 19% of their patients were currently using monoclonal antibodies. For almost all patients, restricted QoL (100%) and number of mean monthly migraine days (MMD) (98.8%) were the main reasons to start treatment with a monoclonal antibody. Physicians reported that 82.7% of their patients responded to erenumab and that 79.5% were satisfied with it. Erenumab reduced headache intensity in 77.4% of patients, improved QoL in 75.5%, and reduced MMD by half in 66%. Physicians also reported that 69.4% of their patients already had a response after the first injection. Mean change in MMD was -6.3; mean change in acute medication days was -6.4.

Keywords: Migraine Disorders; Erenumab; TELESCOPE; Calcitonin Gene-Related Peptide

  1. Straube P, et al. P3.005, AAN 2020.

Top image: @ iStockPhoto: koto_feja

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.